BioSpace News Archive

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 4:05 p.m. ET.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced management’s participation in two upcoming investor conferences

Virax Biolabs Group Limited announced that Virax’s Chairman of the Board of Directors and Chief Executive Officer, Mr. James Foster will present at H.C. Wainwright’s 24th Annual Global Investment Conference, held from September 12-14, 2022, in New York, NY.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12th at 7:00am EST.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate at two upcoming investor conferences.

NANOBIOTIX announced that Laurent Levy, Co-Founder and Chief Executive Officer of Nanobiotix, has been named to the PharmaVoice 100 list of the most inspiring people in the life sciences.

Centene Corporation announced it will present at the Morgan Stanley 20th Annual Global Healthcare Conference, to be held Monday, September 12th – Wednesday, September 14th in New York City.

Freeline Therapeutics Holdings plc announced that on August 31, 2022, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 64,050 of the Company’s ordinary shares.

Valneva SE, a specialty vaccine company, announces that The Lancet Infectious Diseases, a peer-reviewed medical journal, has published the Company’s pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.

IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that its partner Ipsen has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan.